Brain Health

/
Brain Health


Brain Health

Chair: Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers

11:35-11:55 Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers: “Where are we in Research, Treatment and Prevention of Alzheimer Disease and Dementia? – Lessons in Drug Development from the Past Year and the Status of the Current Drugs in Late-phase Development“

11:55-13:05 Panel: “Innovations In-development” to Improve Treatment for Brain Diseases – Challenge the Traditional Drug Development Frameworks
Moderator: Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers
Panelists: :
Mark Carlton, CSO, Cerevance Therapeutics
Michal Schnaider Beeri, PhD, Director, Joseph Sagol Neuroscience Center
Michael C. Irizarry, Vice-President of Early Phase Neurosciences, Eli Lilly
Michael Martin, PhD, Global Head, Takeda Ventures, Inc
Yuval Mor, CEO, Beyond Verbal: “Using Voice and AI to Revolutionize Healthcare by Discovering Vocal Biomarkers”

13:05-13:20 Eyal Baror, CEO, Neuronix Medical

13:20-13:35 Gili Hart, CEO, Mitoconix: “Treating Neurodegeneration by Improving Mitochondria Health”

13:35-15:05 Lunch Break

15:05-16:05 Panel: Getting Closer to Validated Biomarkers
Moderator: Tetsuyuki Maruyama, PhD, Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers
Panelists:
Prof. John Gallacher, Director, Dementia Platform UK, University of Oxford
Michael C. Irizarry, Vice-President of Early Phase Neurosciences, Eli Lilly
Prof. Nir Giladi, MD, Director, Neurology Division, Tel Aviv Sourasky Medical Center

16:05-16:20 Sefi Epel, CEO, BrainMarc: “No Pain No Gain”

16:20-16:35 Adam Shames, Director of Business Development & Strategy, Brainsway: “Deep TMS for the Aging Population”

16:35-16:50 Michal Izrael, VP of R&D ALS & Neurodegenerative Diseases, Kadimastem: “Human Pluripotent Stem Cell Derived Astrocytes for the Treatment of ALS, and Insuling Secreting Islets for the Treatment of Diabetes”

16:50-17:05 Ehab Shakour, CEO, InnoSphere: “InnoSphere Overview”

17:05-17:20 Prof. Jonathan Javitt, Founder & CEO, NeuroRx, Inc: “Suicide is a Druggable Target: Treating Suicidal Depression and PTSD with a Small Molecule NMDA/5-HT2A Dual-targeted Drug Platform”

By | 2018-05-16T14:04:08+00:00 February 19th, 2018|Comments Off on
Brain Health

About the Author: